Based on the findings of BOLERO‐2 and BOLERO‐5, as well as real‐world studies, everolimus and exemestane combination therapy may be used in patients with HR‐positive/HER2‐negative advanced breast cancer after treatment failure with endocrine monotherapy or combined therapy. Here, ERBB2 is linked to breast carcinoma.